MS Clinical Trials in California

67 active trials · 29 recruiting

67 active multiple sclerosis clinical trials have at least one study site in California, 29 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.

Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 29 MS treatment centers in California; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.

Active MS trials with sites in California

RecruitingPhase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Sponsor: TG Therapeutics, Inc.

Ublituximab · Placebo

25 states800 participantsDetails ›

RecruitingPhase 1

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

RO7121932 IV · RO7121932 SC

5 states129 participantsDetails ›

RecruitingPhase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Sponsor: Amgen

Ocrelizumab (US) · Ocrelizumab (EU)

17 states444 participantsDetails ›

RecruitingPhase 2

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Sponsor: Hoffmann-La Roche

Ocrelizumab Test Formulation · Ocrelizumab Reference Formulation

8 states182 participantsDetails ›

RecruitingPhase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Sponsor: National Cancer Institute (NCI)

Biospecimen Collection · Nivolumab

19 states300 participantsDetails ›

RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Remibrutinib (blinded) · Placebo

10 states1275 participantsDetails ›

RecruitingPhase 1

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Sponsor: Autolus Limited

Obecabtagene autoleucel (obe-cel)

1 state18 participantsDetails ›

RecruitingPhase 3

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Frexalimab

6 states160 participantsDetails ›

RecruitingPhase 1

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Sponsor: University of California, San Francisco

Clemastine Fumarate · Placebo

1 state74 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Teriflunomide

35 states1600 participantsDetails ›

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

No Intervention

29 states500 participantsDetails ›

RecruitingPhase 1

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Sponsor: Stanford University

KYV-101 anti-CD19 CAR-T cell therapy · Standard lymphodepletion regimen

1 state12 participantsDetails ›

Recruiting

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

Sponsor: TG Therapeutics, Inc.

No intervention

4 states16 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Placebo

38 states900 participantsDetails ›

RecruitingNA

Central Vein Sign in Multiple Sclerosis Extension Study

Sponsor: The Cleveland Clinic

MRI Contrast

3 states40 participantsDetails ›

RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

CC-97540 · Fludarabine

14 states120 participantsDetails ›

RecruitingPhase 3

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Sponsor: Celgene

Ozanimod · Fingolimod

9 states194 participantsDetails ›

RecruitingPhase 3

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Autologous Hematopoietic Stem Cell Tr… · Best Available Therapy (BAT)

15 states156 participantsDetails ›

Recruiting

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

Sponsor: TScan Therapeutics, Inc.

Companion blood samples with procedure

9 states300 participantsDetails ›

Recruiting

Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

Sponsor: University of California, San Francisco

1 state300 participantsDetails ›

Recruiting

Care in Multiple Sclerosis (MS)

Sponsor: NYU Langone Health

6 states386 participantsDetails ›

RecruitingNA

ECoG BMI for Motor and Speech Control

Sponsor: Karunesh Ganguly

PMT/Blackrock Combination Device

1 state3 participantsDetails ›

Recruiting

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

Sponsor: University of California, San Francisco

1 state250 participantsDetails ›

RecruitingPhase 1

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Sponsor: Ashvattha Therapeutics, Inc.

18F-OP-801

2 states65 participantsDetails ›

Recruiting

Kesimpta (Ofatumumab) Pregnancy Registry

Sponsor: Novartis Pharmaceuticals

Kesimpta

1 state725 participantsDetails ›

RecruitingPhase 1

Entire-body PET Scans for Multiple Sclerosis

Sponsor: Brain Health Alliance

Entire-body PET-CT scans · Amyvid radiopharmaceutical

1 state20 participantsDetails ›

RecruitingNA

Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)

Sponsor: University of Southern California

Med Diet. Investigators would like to…

1 state50 participantsDetails ›

Recruiting

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

Sponsor: Novartis Pharmaceuticals

Siponimod

1 state867 participantsDetails ›

Recruiting

MS-ResearchBiomarkerS

Sponsor: Cedars-Sinai Medical Center

1 state1000 participantsDetails ›

By invitation onlyPhase 4

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Sponsor: University of California, San Francisco

Ocrelizumab

1 state5 participantsDetails ›

By invitation only

Serum Auto-Antibodies in Neurological Diseases

Sponsor: University of California, Davis

Blood Draw · Cheek swab

1 state120 participantsDetails ›

By invitation only

Quest to Analyze One Thousand Humans Meditating

Sponsor: Tobias Moeller-Bertram

Advanced multi-component meditation p…

1 state3000 participantsDetails ›

Closed to new patientsPhase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Disease modifying treatment (DMT)

19 states136 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

23 states1011 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

16 states769 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Fingolimod · Ofatumumab

6 states129 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 4

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Ofatunumab

4 states24 participantsDetails ›

Closed to new patientsPhase 3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Sponsor: Novartis Pharmaceuticals

Ofatumumab approved dose · Ofatumumab new dose

24 states196 participantsDetails ›

Closed to new patientsPhase 3

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

13 states751 participantsDetails ›

Closed to new patientsPhase 2

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

Sponsor: Emmanuelle Waubant, MD PhD

N-acetyl cysteine · Placebo

1 state98 participantsDetails ›

Closed to new patientsPhase 3

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Tetanus toxoid (TT) containing vaccin…

32 states1882 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

27 states1001 participantsDetails ›

Closed to new patientsPhase 3

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Sponsor: TG Therapeutics, Inc.

Ublituximab

14 states1100 participantsDetails ›

Closed to new patientsNA

Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study

Sponsor: University of California, San Francisco

WeB · Standard pelvic floor physical therapy

1 state20 participantsDetails ›

Closed to new patientsPhase 3

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Sponsor: Immunic AG

IMU-838 tablets · Placebo matching IMU-838 tablets

4 states1121 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

20 states864 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

23 states746 participantsDetails ›

Closed to new patientsPhase 3

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Sponsor: Sanofi

Tolebrutinib · Placebo

27 states2500 participantsDetails ›

Closed to new patientsPhase 2

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Placebo

2 states109 participantsDetails ›

Closed to new patientsPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

26 states1300 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab Placebo

11 states188 participantsDetails ›

Closed to new patientsNA

VIRtual Versus UsuAL In-office Care for Multiple Sclerosis (VIRTUAL-MS)

Sponsor: The Cleveland Clinic

Multiple Sclerosis Clinical Care Deli… · Multiple Sclerosis Clinical Care Deli…

2 states120 participantsDetails ›

Closed to new patientsPhase 4

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Sponsor: University of California, San Francisco

Ocrelizumab

1 state30 participantsDetails ›

Closed to new patientsPhase 1

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Sponsor: Bruce Cree

KYV-101 (Biological) - 0.33 ×10^8 cells · KYV-101 (Biological) - 1 ×10^8 cells

1 state10 participantsDetails ›

Closed to new patientsPhase 3

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Interferon beta-1a · Fingolimod

8 states240 participantsDetails ›

Closed to new patientsPhase 2

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Sponsor: Zenas BioPharma (USA), LLC

Obexelimab · Placebo

11 states93 participantsDetails ›

Closed to new patientsNA

Multiple Sclerosis Falls Insight Track

Sponsor: University of California, San Francisco

MS FIT: Falls Insight Track

1 state100 participantsDetails ›

Closed to new patientsNA

A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis

Sponsor: University of California, San Francisco

MS CATCH

1 state100 participantsDetails ›

Showing 60 of 67. See all in the directory.

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Active MS trials with sites in California

MS trials in other states